FibroBiologics

About FibroBiologics

FibroBiologics is a company focused on developing fibroblast cell-based therapies to treat and potentially cure chronic diseases. They harness the power of fibroblasts, the most common cell in the human body, as a practical and economical alternative to stem cells for tissue and organ regeneration.

Products & Services

Fibroblast Cell-Based Therapies:Therapies using fibroblasts for tissue regeneration and immune modulation, targeting chronic conditions and organ decline.

CNS Disorders (Multiple Sclerosis):Therapies showing promising pre-clinical and clinical trial data for treating autoimmune diseases like Multiple Sclerosis.

Thymus Therapy:Exploring fibroblast therapies to improve and extend the productive life of the thymus as it declines with age.

Degenerative Disc Disease (DDD):Using fibroblasts as a potential substitute for Mesenchymal stem cells in treating DDD.

Skin (Wound Healing):Leveraging fibroblasts' natural role in the wound healing process for therapeutic applications.

Fibroblast cell-based therapies for CNS disorders (Multiple Sclerosis)

Fibroblast therapies for thymus regeneration

Fibroblast therapies for spleen regeneration

Fibroblast therapies for Degenerative Disc Disease (DDD)

Fibroblast therapies for skin wound healing

Specialties

Fibroblast Cell-Based Therapies Tissue and Organ Regeneration Immune Modulation Chronic Disease Treatment Fibroblast cell-based therapies Regenerative medicine Immune modulation Autoimmune disease treatment CNS disorders (Multiple Sclerosis) Thymus regeneration Spleen regeneration Degenerative Disc Disease (DDD) Wound healing

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement, Public Offering T: - FT: Private Placement, Public Offering	A: 6000000 MR: - FA: $6M FAN: 6000000	D: 2026-07-31 FD: 2026-07-31	-
2	RT: Private Placement T: - FT: Private Placement	A: 3000000 MR: - FA: 3.0 million upfront (up to 9.0 million total with warrants) FAN: 3000000	D: 2026-06-29 FD: 2026-06-29	-
3	RT: Private Placement T: - FT: Private Placement	A: 9000000 MR: - FA: up to $9.0 Million FAN: 9000000	D: 2026-06-26 FD: 2026-06-26	-
4	RT: Public Offering T: - FT: Public Offering	A: 3000000 MR: - FA: approximately $3 million FAN: 3000000	D: 2026-04-02 FD: 2026-04-02	1 investors
5	RT: Public Offering T: - FT: Public Offering	A: 3000000 MR: - FA: $3 million FAN: 3000000	D: 2026-03-31 FD: 2026-03-31	1 investors
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1700000 MR: - FA: approximately $1.7 million FAN: 1700000	D: 2025-12-16 FD: 2025-12-16	1 investors
7	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1700000 MR: - FA: $1.7 million FAN: 1700000	D: 2025-12-15 FD: 2025-12-15	-
8	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1500000 MR: - FA: $1.5 million FAN: 1500000	D: 2025-11-25 FD: 2025-11-25	1 investors
9	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1500000 MR: - FA: approximately $1.5 million FAN: 1500000	D: 2025-11-24 FD: 2025-11-24	-
10	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4000000 MR: - FA: $4 million FAN: 4000000	D: 2025-11-19 FD: 2025-11-19	1 investors
11	RT: Convertible Debt T: - FT: Convertible Debt	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2025-06-16 FD: 2025-06-16	1 investors
12	RT: Convertible Debt T: - FT: Convertible Debt	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2024-12-30 FD: 2024-12-30	1 investors
13	RT: Convertible Debt T: - FT: Convertible Debt	A: 25000000 MR: - FA: 25 million FAN: 25000000	D: 2024-12-30 FD: 2024-12-30	1 investors
14	RT: Convertible Debt T: - FT: Convertible Debt	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2024-12-23 FD: 2024-12-23	1 investors
15	RT: Equity Crowdfunding T: - FT: Equity Crowdfunding	A: 6900 MR: - FA: surpassing $6,900 per investor FAN: 6900	D: 2023-02-24 FD: 2023-02-24	1 investors
16	RT: Equity Crowdfunding T: - FT: Equity Crowdfunding	A: 1000000 MR: - FA: $1 million FAN: 1000000	D: 2023-02-01 FD: 2023-02-01	2 investors

Private Placement, Public Offering Latest

2026-07-31

$6.0M

Private Placement 2026-06-29

$3.0M

Private Placement 2026-06-26

$9.0M

View 15 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

FibroBiologics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised